Hypomethylating agents combined with low-dose chemotherapy for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: a real-world clinical experience.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of chemotherapy"
DOI: 10.1080/1120009x.2022.2097433
Abstract: This study aimed to assess the efficacy and safety of hypomethylating agent (HMA)-based regimens in the treatment of older adult patients with acute myeloid leukaemia (AML), unfit for standard induction chemotherapy. Treatment outcomes and prognostic… read more here.
Keywords: intensive chemotherapy; unfit intensive; dose chemotherapy; patients acute ... See more keywords